Watch for These Anti Aging Companies Progressing Longevity Research Through Cellular Reprogramming

Aging biology is a largely unexplored segment of the healthcare industry; currently, various researchers are working to identify the different biological as well as genetic mechanism that contribute to aging We analyzed more than 70 anti aging drugs. In this article, discover the top 5 anti aging companies (start-ups) engaged in developing therapeutics that focus on cellular reprogramming for extending healthy lifespan in humans.

---

Aging refers to the progressive changes (behavioral, biological, physiological and psychological) that occur in an individual, resulting in senescence of cells or reduction in the normal bodily functions of an organism. The different causes of aging include epigenetic changes, genomic instability, mitochondrial dysfunctioning, oxidative damage and telomere shortening. Further, as per the World Health Organization, 1 in 6 people in the world will be aged 60 years or over, by 2030.¹ 

As a result, researchers are putting in a continuous effort to understand the biology and mechanisms of aging process, and develop innovative interventions that promote healthier and longer lives. Several potential candidates are presently being evaluated in preclinical as well as clinical studies, across the world. It is worth mentioning that cellular reprogramming approach has gained significant traction in the anti ageing industry, over the past few years; this can be attributed to its ability to reset the epigenetic aging clock, elongate telomeres and evade replicative senescence. Another significant development amongst the others in anti aging market is the use of AI in drug discovery. Recently, University of Edinburgh revealed discovery of drugs to combat ageing using machine learning platorm.²

In the last few years, the anti aging companies have seen support from billionaires of the like of Jeff Bezos, Larry Ellison and Peter Thiel amongst others. Roots Analysis has conducted an exhaustive study on Anti-aging Market, featuring the current market landscape and future opportunities for anti aging companies developing anti aging drugs.

Table of Contents

Below, we have listed (in alphabetical order), the top 5 anti aging companies established post 2017 (focused on cellular reprogramming):
1. Altos Labs
2. Life Biosciences 
3. New Limit
4. Shift Bioscience
5. Turn Biotechnologies

Interested in exploring all 70+ anti aging drugs and their developers across various regions?

Collaboratively with Prominent Scientists, Clinicians and Industrial Leaders, Altos Labs Aims to Unravel Longevity Research Through Cellular Rejuvenation

Altos Labs focuses on reversing cellular damage caused due to injury / disease and rejuvenates the tissue health by unlocking the biological benefits of cellular programming. The company claims to have noble laureates and scientific leaders as its advisors and Board of Directors. Further, it aims to integrate the scientific expertise of academia and industry, to develop transformative medications. The company has reportedly received investment from Amazon founder Jeff Bezos.

The following table presents the details of the anti aging drugs developed by Altos Labs.

S. No	Therapy Name	Phase of Development	Mechanism of Action
1	Unnamed	Discovery	Cellular Rejuvenation Programming

 

Recent Developments: 

• In June 2022, Altos Labs signed a sponsored agreement with Kyoto University’s Center for iPS Cell Research and Application (CiRA), to fund four research projects of the latter organization for five years;  the agreement focuses on unravelling the potential of cellular rejuvenation programming in improving the tissue function.
• In January 2022, the company raised USD 3 billion in seed funding round, to investigate the potential of cellular rejuvenation programming in reversing disease, injury and disability. The funding was led by two investors, Yuri Milner and Jeff Bezos.

Further information related to the company’s initiatives in the anti aging industry is available in the full report.

Raising a Substantial Amount Through Funding, Life Biosciences Strengthened its Research and Development Initiatives for Innovative Anti Aging Drugs

Life Biosciences leverages its innovative platform to develop medicines having the potential to prevent, cure or reverse multiple age-related indications. The firm’s researchers and scientists stay at the forefront of research and innovations in the anti aging industry by publishing their literature in various peer-reviewed journals. Oracle co-founder Larry Ellison has invested in the company.

The following table presents the details of the anti aging drugs developed by Life Biosciences.

S. No	Therapy Name	Phase of Development	Mechanism of Action
1	Unnamed	Preclinical	Partial Epigenetic Reprogramming

 

Recent Developments: 

• In May 2023, Life Biosciences entered into a partnership with Forge Biologics to advance the development and manufacturing of adeno-associated virus (AAV) for the former company’s partial epigenetic reprogramming technology.
• In February 2023, the company participated in Roadmap to Healthy Longevity: Enabling Healthier, Longer Lives in the GCC conference, held in Riyadh, Saudi Arabia to highlight the ongoing developments in the healthcare domain and showcase the firms’ pipeline.
• In April 2022, the company participated in fourth annual Longevity Leaders World Congress, held in London, UK  to highlight the different mechanisms involved in the aging process and discuss about the firm’s initiatives.
• In January 2022, the firm raised USD 82 million in venture (series C) funding, to advance its three platforms that target fundamental biological mechanisms contributing to aging. 

Further information related to the company’s initiatives in the anti aging industry is available in the full report.

With an Aim to Extend Human Lifespan, NewLimit is Building Screening Technologies to Test Different Reprogramming Strategies

NewLimit focuses on leveraging functional assays, single cell multi-omics and machine learning to uncover the biology of epigenetic aging and its associated diseases. The firm conducts in-house research as well as collaborates with leading academic and clinical players, to develop innovative drugs for diseases with large unmet needs.

The following table presents the details of the anti aging drugs developed by NewLimit.

S. No	Therapy Name	Phase of Development	Mechanism of Action
1	Unnamed	Discovery	Partial Epigenetic Reprogramming

 

Recent Developments: 

• In May 2023, the firm raised USD 40 million in venture (series A) financing, to discover transcription factors that can epigenetically reprogram cells to treat aging and age-related diseases. The funding round was co-led by Dimension, Founders Fund and Kleiner Perkins, with participation from Eric Schmidt, Elad Gil, Garry Tan and Fred Ehrsam.
• In April 2023, the firm completed its first partial reprogramming screening in human T-cell (of healthy young as well as old donors).³

Further information related to the company’s initiatives in the anti aging industry is available in the full report.

Leveraging its Deep Learning Models, Shift Bioscience Strives to Identify Rejuvenation Factors That Reset the Cells / Tissues to a Youthful Form

Shift Bioscience employs machine learning to identify, improve and validate the suitable set of transcription factors that control cellular rejuvenation. Owing to the skills of its scientific team and funding received from investors, the company offers advanced screening (of genes), rejuvenation screening (of new drugs) and toxicological screening (of new drugs).

The following table presents the details of the anti aging drugs developed by Shift Bioscience.

S. No	Therapy Name	Phase of Development	Mechanism of Action
1	Unnamed	Discovery	Cellular Reprogramming

 

Recent Developments: 

• In April 2023, the company won Innovate UK SMART grant from Innovate UK, a part of UK Research and Innovation which offers funding for cutting-edge innovations having potentially significant impact on the UK economy.
• In February 2022, the company closed a seed funding round.

Further information related to the company’s initiatives in the anti aging industry is available in the full report.

Overcoming the Challenge of T-cell Exhaustion and Aging, Turn Bio Maximizes Efficiency Using its Proprietary Technologies (ERA and eTurna)

Turn Biotechnologies focuses on the development of mRNA therapeutics (using its proprietary Epigenetic Reprogramming of Aging (ERA) platform), thereby repairing the damage caused by aging process. The company aims to treat various illnesses and conditions related to dermatology, immunology, osteoarthritis and ophthalmology by reprogramming different cells to rejuvenate the body. In September 2022, the company launched a novel platform, namely eTurna to enhance the safe and efficacious delivery of nucleic acid therapeutics. Their lead program is TRN-001, which is expected to enter phase I clinical trials in late 2023 / early 2024.⁴

The following table presents the details of the anti aging drugs developed by Turn Biotechnologies.

S. No	Therapy Name	Phase of Development	Mechanism of Action
1	TRN-001	Preclinical	Cellular Reprogramming
2	TRN-006	Preclinical	Cellular Reprogramming
3	TRN-010	Preclinical	Cellular Reprogramming
4	TRN-003	Preclinical	Cellular Reprogramming
5	TRN-004	Preclinical	Cellular Reprogramming
6	TRN-007	Discovery	Cellular Reprogramming
7	TRN-008	Discovery	Cellular Reprogramming

 

Recent Developments: 

• In June 2023, the company participated in SEASON Aesthetic Conference 2023, held in London, UK to discuss the benefits of epigenetic reprogramming delivered through the firm’s eTurna carrier system to rejuvenate skin cells.
• In June 2023, the company participated in 23rd Annual Meeting of the Japanese Society of Anti-Aging Medicine (JAAM), held in Tokyo, Japan to discuss the potential of epigenetic reprogramming in reversing cellular aging.
• In May 2023, the company participated in International Societies for Investigative Dermatology (ISID) Meeting, held in Tokyo, Japan to present the potential of the company’s ERA technology in enhancing fibroblast proliferation as well as reversing the intrinsic hallmarks of aging.
• In April 2023, the company participated in SEASON Aesthetic Conference, held in London, UK to demonstrate the potential of company’s transformative technology to reprograms cells.
• In April 2023, the company participated in World Oncology Cell Therapy Congress, held in Massachusetts, US to discuss the prospects of ERA technology in enhancing the efficacy of T-cells against tumor cells.
• In April 2023, the company participated in American Association for Cancer Research Annual Meeting, held in Florida, US to demonstrate the efficiency of ERA technology in increasing T-cell proliferation in tumor cells.
• In February 2023, the company participated in Next Generation CAR & T Cell Therapies Conference, held in California, US to present the cancer-killing capacity of ERA-treated T cells.
• In April 2022, the firm raised an undisclosed amount through investments from Daewoong Pharmaceutical and HanAll Biopharma; the funding provided aims to support the development of the former company’s novel cell rejuvenating technology (for different therapeutic indications) and initiate phase I trial of its mRNA therapy, TRN-001.

Further information related to the company’s initiatives in the anti aging industry is available in the full report.

What About the Other Anti Aging Companies Developing Drugs?

The above presentation features the top 5 anti aging companies selected from a pool of over 65 firms that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

About Author

Simran Kaur

Simran, a Senior Business Analysis, has been an integral part of the Roots Analysis team since 2020. Holding a Master’s and Bachelor’s in pharmacy from a prestigious institution, she embarked on her professional journey with a strong academic foundation and an interest in life sciences domain. Her keenness to learn more about the emerging trends, regulatory dynamics and technological advancements enables her to provide comprehensive analyses. Till date, she has diligently contributed to over 15 comprehensive research reports on trending topics, ranging from anti-aging therapeutics, allogeneic cell therapies, lipid nanoparticles, pre-sterilized pharmaceutical packaging to next generation sequencing kits.

Source:1 https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
Source:2 https://www.ed.ac.uk/news/2023/ai-algorithms-find-drugs-that-could-combat-ageing
Source:3 https://blog.newlimit.com/p/april-2023-progress-update
Source:4 https://www.sciencetimes.com/articles/39805/20220908/promising-hair-follicle-claims-treat-baldness-one-time.htm#:~:text=Sebastiano%20is%20aiming%20to%20start,application%20with%20microintegrations%2C%20he%20added